Anixa Biosciences Inc financial data

Symbol
ANIX on Nasdaq
Location
San Jose, CA
Fiscal year end
31 October
Latest financial report
10-Q - Q2 2025 - 10 Sep 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 879 % -33.5%
Debt-to-equity 13.1 % +55.7%
Return On Equity -67.5 % -23.1%
Return On Assets -59.2 % -17.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.9M shares +2.29%
Common Stock, Shares, Outstanding 32.8M shares +2.1%
Entity Public Float 90.6M USD -24.9%
Common Stock, Value, Issued 328K USD +2.18%
Weighted Average Number of Shares Outstanding, Basic 32.5M shares +1.32%
Weighted Average Number of Shares Outstanding, Diluted 32.5M shares +1.32%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 210K USD
Revenue from Contract with Customer, Excluding Assessed Tax 210K USD
Research and Development Expense 5.41M USD -17.3%
General and Administrative Expense 6.58M USD -8.37%
Costs and Expenses 12M USD -12.6%
Operating Income (Loss) -12M USD +12.6%
Net Income (Loss) Attributable to Parent -11.1M USD +10.1%
Earnings Per Share, Basic 0 USD/shares +36.4%
Earnings Per Share, Diluted 0 USD/shares +36.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.5M USD +22%
Cash, Cash Equivalents, and Short-term Investments 20.7M USD
Assets, Current 17.4M USD -23%
Operating Lease, Right-of-Use Asset 202K USD -15.1%
Assets 17.7M USD -22.9%
Accounts Payable, Current 276K USD -8.61%
Accrued Liabilities, Current 1.75M USD +4.35%
Liabilities, Current 2.07M USD +3.09%
Operating Lease, Liability, Noncurrent 174K USD -18.3%
Liabilities 2.24M USD +1.04%
Retained Earnings (Accumulated Deficit) -249M USD -4.67%
Stockholders' Equity Attributable to Parent 16.6M USD -23.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 15.4M USD -25.5%
Liabilities and Equity 17.7M USD -22.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.9M USD -25.8%
Net Cash Provided by (Used in) Financing Activities -17K USD -101%
Net Cash Provided by (Used in) Investing Activities 2.7M USD +1995%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 32.8M shares +2.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -218K USD -363%
Deferred Tax Assets, Valuation Allowance 34.5M USD +16.6%
Deferred Tax Assets, Gross 34.5M USD +16.6%
Operating Lease, Liability 213K USD -10.1%
Lessee, Operating Lease, Liability, to be Paid 271K USD -16.4%
Operating Lease, Liability, Current 39K USD +62.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 64K USD +1.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 63K USD +12.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 58K USD -33.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 66K USD +1.54%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 19.9K shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 63K USD -4.55%
Additional Paid in Capital 265M USD +2.29%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 100 USD/shares 0%